Home/Filings/4/0001437749-25-021050
4//SEC Filing

KLEMP WALTER V 4

Accession 0001437749-25-021050

CIK 0001659617other

Filed

Jun 22, 8:00 PM ET

Accepted

Jun 23, 4:35 PM ET

Size

17.1 KB

Accession

0001437749-25-021050

Insider Transaction Report

Form 4
Period: 2025-06-20
KLEMP WALTER V
DirectorCEO and President
Transactions
  • Exercise/Conversion

    Common Stock

    2025-06-20+3,75062,046 total
  • Tax Payment

    Common Stock

    2025-06-20$0.27/sh914$24461,132 total
  • Exercise/Conversion

    Common Stock

    2025-06-22+8,99070,122 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-06-228,990382,456 total
    Common Stock (8,990 underlying)
  • Purchase

    Common Stock

    2025-06-23$0.37/sh+675,675$250,000743,607 total
  • Tax Payment

    Common Stock

    2025-06-22$0.27/sh2,190$58567,932 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-06-203,750391,446 total
    Common Stock (3,750 underlying)
  • Purchase

    Series E Warrants

    2025-06-232,027,0252,409,481 total
    Exercise: $0.37Common Stock (2,027,025 underlying)
Footnotes (5)
  • [F1]Restricted stock units convert into common stock on a one-for-one basis.
  • [F2]Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
  • [F3]On June 20, 2022, the reporting person was granted 15,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
  • [F4]On June 22, 2023, the reporting person was granted 35,959 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
  • [F5]On June 23, 2025, the reporting person acquired 675,675 shares of common stock and Series E warrants to purchase 2,027,025 shares of common stock at a purchase price of $0.37 per share and accompanying warrants in a public offering. The Series E warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series E warrants and will expire five years from the date of such approval.

Issuer

Moleculin Biotech, Inc.

CIK 0001659617

Entity typeother

Related Parties

1
  • filerCIK 0000938419

Filing Metadata

Form type
4
Filed
Jun 22, 8:00 PM ET
Accepted
Jun 23, 4:35 PM ET
Size
17.1 KB